OR WAIT null SECS
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
Catalent will use T-knife´s TCR platform for a T-cell receptor-based cell therapy at its Gosselies, Belgium, site in order to manufacture clinical batches for European trials in 2021.
Catalent announced on Sept. 21, 2020 that it has entered into an agreement with T-knife, a Germany-based T-cell company, for the technology transfer and clinical manufacturing of T-knife’s tumor-targeting T1367 T-cell receptor (TCR) program.
Through the agreement, Catalent will use T-knife´s TCR platform for a T-cell receptor-based cell therapy at its Gosselies, Belgium, site in order to manufacture clinical batches for European trials in 2021, a Catalent press release said. T-knife will also transfer the TCR platform to Catalent’s Houston, TX, facility for future clinical trials in North America.
“The product candidates based on our proprietary HuTCR platform require sophisticated, state-of-the-art manufacturing capabilities and deep cell and gene therapy know-how,” said Michael Buchholz, director, Manufacturing, at T-knife, in the press release. “We are convinced that Catalent is the right partner for T-knife to ensure premier manufacturing of our pipeline programs, covering all stages from clinical trials to market.”
“Catalent is well-suited to support T-knife with focused technology transfer and process industrialization in both Gosselies and Houston,” added Manja Boerman, PhD, president, Cell and Gene Therapy, Catalent, in the press release. “Emerging and innovative treatments like T1367 are moving rapidly to the clinic. Catalent is committed to continual investment and expansion to support our clients as they continue on the journey to commercialization.”